View ValuationBioGaia 향후 성장Future 기준 점검 3/6BioGaia (는) 각각 연간 16.4% 및 9.8% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 16.4% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 38.2% 로 예상됩니다.핵심 정보16.4%이익 성장률16.37%EPS 성장률Biotechs 이익 성장25.4%매출 성장률9.8%향후 자기자본이익률38.20%애널리스트 커버리지Low마지막 업데이트07 Apr 2026최근 향후 성장 업데이트공시 • Oct 17Biogaia AB (Publ) Provides Preliminarily Earnings Guidance for Third Quarter 2023BioGaia AB (publ) provided preliminarily earnings guidance for third quarter 2023. For the third quarter, sales are preliminarily estimated at SEK 318 million, an increase of 23% (excluding foreign exchange effects, 17%). The operating profit for the third quarter is preliminarily estimated at SEK 120 million, an increase of 28%.모든 업데이트 보기Recent updates공시 • Feb 13BioGaia AB (publ), Annual General Meeting, May 07, 2026BioGaia AB (publ), Annual General Meeting, May 07, 2026.공시 • Feb 12+ 1 more updateBiogaia AB (Publ) Proposes Extra DividendBioGaia AB (publ) announced that the board will propose at the upcoming Annual General Meeting on 7 May 2026 an extra dividend of SEK 2.36 per share (4.95 per share).공시 • Oct 22+ 2 more updatesBioGaia AB (publ) to Report Fiscal Year 2025 Results on Feb 12, 2026BioGaia AB (publ) announced that they will report fiscal year 2025 results at 8:00 AM, Central European Standard Time on Feb 12, 2026공시 • Oct 13BioGaia AB (publ) to Report Q3, 2025 Results on Oct 22, 2025BioGaia AB (publ) announced that they will report Q3, 2025 results at 8:00 AM, Central European Standard Time on Oct 22, 2025공시 • Aug 22BioGaia AB (publ) Elects Mauricio Graber as New Board Member and Chairman of the BoardAt an extraordinary general meeting of BioGaia AB (publ) on 22 August 2025, it was resolved to elect Mauricio Graber as new board member and chairman of the board, following Peter Rothschild's decision to resign as board member and chairman.공시 • Jul 25Biogaia AB (Publ) Announces Resignation of Peter Rothschild as Chairman of the Board and Leave the Board of Directors, Effective At the Extraordinary General Meeting, 22 August 2025BioGaia AB (publ) announced that Peter Rothschild has announced that he will resign as Chairman of the Board and leave the Board of Directors at the Extraordinary General Meeting, 22 August 2025.공시 • May 08+ 1 more updateBioGaia AB (publ) Approves Extra DividendBioGaia AB (publ) announced that at its AGM held on 7 May 2025, the shareholders approved an extra dividend of SEK 4.95 per share.공시 • Mar 21Annwall & Rothschild Investments Ab, David Dangoor and others entered into an agreement to acquire stake in BioGaia AB (publ) (OM : BIOG B)Annwall & Rothschild Investments Ab, David Dangoor and others entered into an agreement to acquire stake in BioGaia AB (publ) (OM : BIOG B) for SEK 756 million on March 20, 2025. The purchase price amounts to SEK 136.33 for each current class A share and SEK 115 for each class B share. Under the transaction, Anatom will acquire 1,776,758 class A shares and 2,273,600 class B shares (including to-be-converted class A shares) (in total, 4.0% of the total number of shares and 16.0% of the total number votes after the share conversion). The other separate entities, owned by a different member of the Kahane family, will acquire 888,380 class A shares and 1,136,800 class B shares (including to-beconverted class A shares) (in total, 2.0% of the total number of shares and 8.0% of the total number votes after the share conversion). After the transaction, including existing shareholdings, Anatom will own 1,776,758 class A shares and 5,580,775 class B shares (7.3% of the total number of shares and 18.7% of the total number votes) and the other separate entities, owned by a different member of the Kahane family, will own 888,380 class A shares and 2,809,438 class B shares (3.7% of the total number of shares and 9.3% of the total number votes). The purchase by Anatom is conditional on approval by the Swedish Inspectorate of Strategic Products. Such approval is expected in a few weeks. The Annual General Meeting of BioGaia The sellers have engaged Rothschild & Co Nordic AB as financial advisor and Vinge as legal advisor in connection with the transaction. Annwall & Rothschild Investments Ab, David Dangoor and others have engaged Gernandt & Danielsson as legal advisor in connection with the transaction.공시 • Feb 26BioGaia AB (publ) announces Annual dividend, payable on May 14, 2025BioGaia AB (publ) announced Annual dividend of SEK 1.9500 per share payable on May 14, 2025, ex-date on May 08, 2025 and record date on May 09, 2025.공시 • Feb 13+ 2 more updatesBioGaia AB (publ) Proposes Extra DividendThe Board of BioGaia AB (publ) proposed that the upcoming Annual General Meeting on 7 May 2025 approves an extra dividend of SEK 4.95 (5.00) per share resulting in a total dividend of SEK 6.90 (6.90) per share, corresponding to SEK 698.0 million (696.8).공시 • Dec 06BioGaia Launches A New Probiotic Supplement, BioGaia® Gastrus® PURE ACTIONBioGaia announced launch BioGaia® Gastrus® PURE ACTION, a clean ingredient, double-strength, FODMAP-friendly probiotic designed to support individuals with sensitive stomachs. This latest addition to BioGaia's product portfolio in adult gut health expands access to specialized advanced, evidence-based solutions for improved digestive health and quality of life. BioGaia® Gastrus® PURE ACTION is formulated with the proprietary, patented probiotic strains L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475, carefully selected for their clinically proven efficacy in managing digestive issues and enhancing gastrointestinal health. The product's twice-daily dosing supports individuals with occasional gut discomfort in regaining control over their digestive health. Vegan capsule and free from sweeteners, lactose, and gluten, BioGaia® Gastrus® PURE ACTION is certified as FODMAP-friendly and designed for sensitive stomachs. These are a group of short-chain carbohydrates and sugar alcohols found in many common foods. They are poorly absorbed in the small intestine, leading to fermentation by gut bacteria, which can cause symptoms like bloating, gas, and diarrhea, especially in people with irritable bowel syndrome (IBS) or other digestive sensitivities. A low-FODMAP diet is often recommended by healthcare professionals to manage symptoms of IBS and other functional gastrointestinal disorders. Product availability: Finland is the first country to launch BioGaia® Gastrus® PURE ACTION, with more country launches to follow. In Finland, the product is available in Pharmacies and main online Pharmacies. Supported by clinical research: The product has been tested in clinical trials and proven to be safe and effective in relieving symptoms like abdominal pain, gas, and bloating. Probiotics in this blend are proven to withstand the harsh conditions of digestive system, ensuring they reach gut alive. The efficacy of BioGaia® Gastrus® PURE ACTION's ingredients was recently evaluated in a randomized, double-blind, placebo-controlled trial involving 140 adults aged 18-65, diagnosed with IBS based on Rome IV criteria. Participants who used the product demonstrated: Significant reduction in IBS symptoms: A notable improvement in the GSRS-IBS score from week 6 onward, with key symptoms such as abdominal pain, bloating, and gas showing marked relief. Enhanced Quality of Life: Participants using BioGaia® Gastrus® PURE ACTION reported significantly higher Quality of Life (QoL-IBS) scores compared to those on the placebo. Reduced inflammation: While not a defining feature of IBS, the study showed that Gastrus reduced low-grade gut inflammation. A second study on the same strain combination suggested it also lowered systemic low-grade inflammation.공시 • Oct 22BioGaia AB (publ) to Report Q2, 2025 Results on Jul 18, 2025BioGaia AB (publ) announced that they will report Q2, 2025 results at 8:00 AM, Central European Standard Time on Jul 18, 2025공시 • Jul 23BioGaia AB (publ) to Report Fiscal Year 2024 Results on Feb 12, 2025BioGaia AB (publ) announced that they will report fiscal year 2024 results at 8:00 AM, Central European Standard Time on Feb 12, 2025공시 • Feb 07+ 1 more updateBiogaia AB (Publ) Proposes an Extra DividendBioGaia AB (publ) proposed an extra dividend of SEK 5.00 (1.45) per share resulting in a total dividend of SEK 6.90 (2.90) per share, corresponding to SEK 696.8 million (292.8 million).공시 • Oct 22+ 1 more updateBioGaia AB (publ) to Report First Half, 2024 Results on Jul 07, 2024BioGaia AB (publ) announced that they will report first half, 2024 results on Jul 07, 2024공시 • Oct 19+ 1 more updateBioGaia AB (publ), Annual General Meeting, Apr 26, 2024BioGaia AB (publ), Annual General Meeting, Apr 26, 2024.공시 • Oct 17Biogaia AB (Publ) Provides Preliminarily Earnings Guidance for Third Quarter 2023BioGaia AB (publ) provided preliminarily earnings guidance for third quarter 2023. For the third quarter, sales are preliminarily estimated at SEK 318 million, an increase of 23% (excluding foreign exchange effects, 17%). The operating profit for the third quarter is preliminarily estimated at SEK 120 million, an increase of 28%.공시 • Sep 26Biogaia AB (Publ) Appoints Theresa Agnew as CEOBioGaia announced that Theresa Agnew begins her role on 25 September 2023, as the Chief Executive Officer of BioGaia. As previously communicated, Theresa Agnew has 20-years of experience in various leadership roles within consumer healthcare, over-the-counter (OTC) drugs, and medical devices from leading companies such as GlaxoSmithKline (GSK), Essilor, and Johnson & Johnson.공시 • Sep 02BioGaia AB (publ) Introduces BioGaia Prodentis KIDS in SwedenBioGaia AB (publ) introduces Prodentis for kids, an apple-flavored lozenge with probiotics and xylitol for oral health, to complement the daily toothbrushing routine. A new addition to the oral health category. Most kids enjoy snacking in between meals, often prefer sugary foods, and have varying enthusiasm for toothbrushing. These habits can lead to unhealthy oral hygiene. Prodentis KIDS contains BioGaia's patented clinically proven probiotic strains L. reuteri ATCC PTA 5289 and L. reuteri DSM 17938 that help the good microorganisms keep a natural balance in the mouth. Prodentis KIDS is specially developed to complement daily toothbrushing routine. From August 2023, Prodentis KIDS will be available for purchase via BioGaia's Swedish webshop, www.biogaia.se as well as the online pharmacies MEDS and Apotea. The recommended retail price is SEK 199.공시 • Aug 03BioGaia Appoints Theresa Agnew as New CEO, Effective September 25, 2023BioGaia's board of directors has appointed Theresa P. Agnew as the new chief executive officer. Theresa Agnew is a global business leader with consumer healthcare, OTC, and medical device experience from leading companies such as GlaxoSmithKline (GSK), Essilor and Johnson & Johnson. She has extensive experience after more than 20 years in leadership roles, managing teams of more than 500 employees. She brings solid international experience having lived and worked in Europe, the US and Australia and the Far East. She has a deep understanding of, and success, in the international healthcare market(s). Theresa holds a B.S. in Biology from Boston College. At GSK she led their OTC global business across multiple segments of Pain Relief, Respiratory Health and Skin Health in OTC pharmaceuticals, naturals, supplements and medical devices in the largest OTC company worldwide. Currently, Theresa Agnew is working at a diabetes start-up, preparing for commercial launch and structuring the company to scale. Theresa Agnew will join the company subject to the successful completion of the pending work permit application process, with an expected starting date as of September 25, or such later date as may be necessary to comply with these requirements.공시 • Jul 06BioGaia's probiotic Protectis increases SARS-CoV-2 antibody response in adultsA randomised, triple-blinded, placebo-controlled study with BioGaia's probiotic Protectis was shown to increase SARS-CoV-2 antibody titres in healthy volunteers when 28 days or more had elapsed from vaccination. It suggests that probiotic supplementation may enhance the long-term protection against breakthrough infections. The study included 159 healthy adults without prior SARS-CoV-2 infection or COVID-19 vaccination. The participants consumed either BioGaia Protectis (Limosilactobacillus reuteri DSM 17938) + 10 microgram vitamin D3, or a placebo product that contained only vitamin D3 for 6 months. During the intervention period 12 subjects were infected, and 17 were fully vaccinated and sampled 28 days or more postvaccination. The purpose of the study was to investigate the effect of probiotic supplementation of BioGaia Protectis on SARS-CoV-2 specific antibody responses after natural infection or vaccination. Even though the primary outcome, based on infected subjects, failed to reach a statistically significant difference between the intervention groups, vaccinated individuals who consumed BioGaia Protectis showed significantly increased IgA antibody levels when 28 days or more had elapsed from vaccination. The study was conducted at the Nutrition-Gut-Brain Interactions Research Centre, Örebro University, Sweden. The results suggest that BioGaia Protectis may improve long-term protection against breakthrough infections after vaccination. The same type of antibodies that are increased by probiotics in this study have previously been shown to be protective against breakthrough infections.이익 및 매출 성장 예측OTCPK:BGLA.F - 애널리스트 향후 추정치 및 과거 재무 데이터 (SEK Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20282,050553524545112/31/20271,839496469486112/31/20261,644420431447112/31/20251,538333303307N/A9/30/20251,462316322325N/A6/30/20251,440287310315N/A3/31/20251,419310351357N/A12/31/20241,423351359373N/A9/30/20241,356337365393N/A6/30/20241,369402360394N/A3/31/20241,300371323379N/A12/31/20231,297365377426N/A9/30/20231,273437361396N/A6/30/20231,213415311342N/A3/31/20231,186413310324N/A12/31/20221,104374301319N/A9/30/20221,036273262284N/A6/30/2022952246286305N/A3/31/2022867222263273N/A12/31/2021785196215222N/A9/30/2021767196215220N/A6/30/2021725164201208N/A3/31/2021766188177190N/A12/31/2020747180205221N/A9/30/2020767194155184N/A6/30/2020802211155189N/A3/31/2020780193147185N/A12/31/2019768187109148N/A9/30/2019770192N/A160N/A6/30/2019778205N/A174N/A3/31/2019756207N/A176N/A12/31/2018742215N/A183N/A9/30/2018702206N/A223N/A6/30/2018675197N/A192N/A3/31/2018631181N/A181N/A12/31/2017615181N/A223N/A9/30/2017584179N/A201N/A6/30/2017562172N/A210N/A3/31/2017542163N/A198N/A12/31/2016535160N/A148N/A9/30/2016500138N/A115N/A6/30/2016480129N/A86N/A3/31/2016478130N/A108N/A12/31/2015483138N/A118N/A9/30/2015500130N/A100N/A6/30/2015474119N/A67N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: BGLA.F 의 연간 예상 수익 증가율(16.4%)이 saving rate(3.4%)보다 높습니다.수익 vs 시장: BGLA.F 의 연간 수익(16.4%)이 US 시장(16.7%)보다 빠르게 성장할 것으로 예상됩니다.고성장 수익: BGLA.F 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: BGLA.F 의 수익(연간 9.8%)이 US 시장(연간 11.7%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: BGLA.F 의 수익(연간 9.8%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: BGLA.F의 자본 수익률은 3년 후 38.2%로 높을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/04/07 16:03종가2026/01/08 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스BioGaia AB (publ)는 3명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Christopher UhdeABG Sundal Collier SponsoredMattias HäggblomDanske BankKristofer Liljeberg-SvenssonDNB Carnegie
공시 • Oct 17Biogaia AB (Publ) Provides Preliminarily Earnings Guidance for Third Quarter 2023BioGaia AB (publ) provided preliminarily earnings guidance for third quarter 2023. For the third quarter, sales are preliminarily estimated at SEK 318 million, an increase of 23% (excluding foreign exchange effects, 17%). The operating profit for the third quarter is preliminarily estimated at SEK 120 million, an increase of 28%.
공시 • Feb 13BioGaia AB (publ), Annual General Meeting, May 07, 2026BioGaia AB (publ), Annual General Meeting, May 07, 2026.
공시 • Feb 12+ 1 more updateBiogaia AB (Publ) Proposes Extra DividendBioGaia AB (publ) announced that the board will propose at the upcoming Annual General Meeting on 7 May 2026 an extra dividend of SEK 2.36 per share (4.95 per share).
공시 • Oct 22+ 2 more updatesBioGaia AB (publ) to Report Fiscal Year 2025 Results on Feb 12, 2026BioGaia AB (publ) announced that they will report fiscal year 2025 results at 8:00 AM, Central European Standard Time on Feb 12, 2026
공시 • Oct 13BioGaia AB (publ) to Report Q3, 2025 Results on Oct 22, 2025BioGaia AB (publ) announced that they will report Q3, 2025 results at 8:00 AM, Central European Standard Time on Oct 22, 2025
공시 • Aug 22BioGaia AB (publ) Elects Mauricio Graber as New Board Member and Chairman of the BoardAt an extraordinary general meeting of BioGaia AB (publ) on 22 August 2025, it was resolved to elect Mauricio Graber as new board member and chairman of the board, following Peter Rothschild's decision to resign as board member and chairman.
공시 • Jul 25Biogaia AB (Publ) Announces Resignation of Peter Rothschild as Chairman of the Board and Leave the Board of Directors, Effective At the Extraordinary General Meeting, 22 August 2025BioGaia AB (publ) announced that Peter Rothschild has announced that he will resign as Chairman of the Board and leave the Board of Directors at the Extraordinary General Meeting, 22 August 2025.
공시 • May 08+ 1 more updateBioGaia AB (publ) Approves Extra DividendBioGaia AB (publ) announced that at its AGM held on 7 May 2025, the shareholders approved an extra dividend of SEK 4.95 per share.
공시 • Mar 21Annwall & Rothschild Investments Ab, David Dangoor and others entered into an agreement to acquire stake in BioGaia AB (publ) (OM : BIOG B)Annwall & Rothschild Investments Ab, David Dangoor and others entered into an agreement to acquire stake in BioGaia AB (publ) (OM : BIOG B) for SEK 756 million on March 20, 2025. The purchase price amounts to SEK 136.33 for each current class A share and SEK 115 for each class B share. Under the transaction, Anatom will acquire 1,776,758 class A shares and 2,273,600 class B shares (including to-be-converted class A shares) (in total, 4.0% of the total number of shares and 16.0% of the total number votes after the share conversion). The other separate entities, owned by a different member of the Kahane family, will acquire 888,380 class A shares and 1,136,800 class B shares (including to-beconverted class A shares) (in total, 2.0% of the total number of shares and 8.0% of the total number votes after the share conversion). After the transaction, including existing shareholdings, Anatom will own 1,776,758 class A shares and 5,580,775 class B shares (7.3% of the total number of shares and 18.7% of the total number votes) and the other separate entities, owned by a different member of the Kahane family, will own 888,380 class A shares and 2,809,438 class B shares (3.7% of the total number of shares and 9.3% of the total number votes). The purchase by Anatom is conditional on approval by the Swedish Inspectorate of Strategic Products. Such approval is expected in a few weeks. The Annual General Meeting of BioGaia The sellers have engaged Rothschild & Co Nordic AB as financial advisor and Vinge as legal advisor in connection with the transaction. Annwall & Rothschild Investments Ab, David Dangoor and others have engaged Gernandt & Danielsson as legal advisor in connection with the transaction.
공시 • Feb 26BioGaia AB (publ) announces Annual dividend, payable on May 14, 2025BioGaia AB (publ) announced Annual dividend of SEK 1.9500 per share payable on May 14, 2025, ex-date on May 08, 2025 and record date on May 09, 2025.
공시 • Feb 13+ 2 more updatesBioGaia AB (publ) Proposes Extra DividendThe Board of BioGaia AB (publ) proposed that the upcoming Annual General Meeting on 7 May 2025 approves an extra dividend of SEK 4.95 (5.00) per share resulting in a total dividend of SEK 6.90 (6.90) per share, corresponding to SEK 698.0 million (696.8).
공시 • Dec 06BioGaia Launches A New Probiotic Supplement, BioGaia® Gastrus® PURE ACTIONBioGaia announced launch BioGaia® Gastrus® PURE ACTION, a clean ingredient, double-strength, FODMAP-friendly probiotic designed to support individuals with sensitive stomachs. This latest addition to BioGaia's product portfolio in adult gut health expands access to specialized advanced, evidence-based solutions for improved digestive health and quality of life. BioGaia® Gastrus® PURE ACTION is formulated with the proprietary, patented probiotic strains L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475, carefully selected for their clinically proven efficacy in managing digestive issues and enhancing gastrointestinal health. The product's twice-daily dosing supports individuals with occasional gut discomfort in regaining control over their digestive health. Vegan capsule and free from sweeteners, lactose, and gluten, BioGaia® Gastrus® PURE ACTION is certified as FODMAP-friendly and designed for sensitive stomachs. These are a group of short-chain carbohydrates and sugar alcohols found in many common foods. They are poorly absorbed in the small intestine, leading to fermentation by gut bacteria, which can cause symptoms like bloating, gas, and diarrhea, especially in people with irritable bowel syndrome (IBS) or other digestive sensitivities. A low-FODMAP diet is often recommended by healthcare professionals to manage symptoms of IBS and other functional gastrointestinal disorders. Product availability: Finland is the first country to launch BioGaia® Gastrus® PURE ACTION, with more country launches to follow. In Finland, the product is available in Pharmacies and main online Pharmacies. Supported by clinical research: The product has been tested in clinical trials and proven to be safe and effective in relieving symptoms like abdominal pain, gas, and bloating. Probiotics in this blend are proven to withstand the harsh conditions of digestive system, ensuring they reach gut alive. The efficacy of BioGaia® Gastrus® PURE ACTION's ingredients was recently evaluated in a randomized, double-blind, placebo-controlled trial involving 140 adults aged 18-65, diagnosed with IBS based on Rome IV criteria. Participants who used the product demonstrated: Significant reduction in IBS symptoms: A notable improvement in the GSRS-IBS score from week 6 onward, with key symptoms such as abdominal pain, bloating, and gas showing marked relief. Enhanced Quality of Life: Participants using BioGaia® Gastrus® PURE ACTION reported significantly higher Quality of Life (QoL-IBS) scores compared to those on the placebo. Reduced inflammation: While not a defining feature of IBS, the study showed that Gastrus reduced low-grade gut inflammation. A second study on the same strain combination suggested it also lowered systemic low-grade inflammation.
공시 • Oct 22BioGaia AB (publ) to Report Q2, 2025 Results on Jul 18, 2025BioGaia AB (publ) announced that they will report Q2, 2025 results at 8:00 AM, Central European Standard Time on Jul 18, 2025
공시 • Jul 23BioGaia AB (publ) to Report Fiscal Year 2024 Results on Feb 12, 2025BioGaia AB (publ) announced that they will report fiscal year 2024 results at 8:00 AM, Central European Standard Time on Feb 12, 2025
공시 • Feb 07+ 1 more updateBiogaia AB (Publ) Proposes an Extra DividendBioGaia AB (publ) proposed an extra dividend of SEK 5.00 (1.45) per share resulting in a total dividend of SEK 6.90 (2.90) per share, corresponding to SEK 696.8 million (292.8 million).
공시 • Oct 22+ 1 more updateBioGaia AB (publ) to Report First Half, 2024 Results on Jul 07, 2024BioGaia AB (publ) announced that they will report first half, 2024 results on Jul 07, 2024
공시 • Oct 19+ 1 more updateBioGaia AB (publ), Annual General Meeting, Apr 26, 2024BioGaia AB (publ), Annual General Meeting, Apr 26, 2024.
공시 • Oct 17Biogaia AB (Publ) Provides Preliminarily Earnings Guidance for Third Quarter 2023BioGaia AB (publ) provided preliminarily earnings guidance for third quarter 2023. For the third quarter, sales are preliminarily estimated at SEK 318 million, an increase of 23% (excluding foreign exchange effects, 17%). The operating profit for the third quarter is preliminarily estimated at SEK 120 million, an increase of 28%.
공시 • Sep 26Biogaia AB (Publ) Appoints Theresa Agnew as CEOBioGaia announced that Theresa Agnew begins her role on 25 September 2023, as the Chief Executive Officer of BioGaia. As previously communicated, Theresa Agnew has 20-years of experience in various leadership roles within consumer healthcare, over-the-counter (OTC) drugs, and medical devices from leading companies such as GlaxoSmithKline (GSK), Essilor, and Johnson & Johnson.
공시 • Sep 02BioGaia AB (publ) Introduces BioGaia Prodentis KIDS in SwedenBioGaia AB (publ) introduces Prodentis for kids, an apple-flavored lozenge with probiotics and xylitol for oral health, to complement the daily toothbrushing routine. A new addition to the oral health category. Most kids enjoy snacking in between meals, often prefer sugary foods, and have varying enthusiasm for toothbrushing. These habits can lead to unhealthy oral hygiene. Prodentis KIDS contains BioGaia's patented clinically proven probiotic strains L. reuteri ATCC PTA 5289 and L. reuteri DSM 17938 that help the good microorganisms keep a natural balance in the mouth. Prodentis KIDS is specially developed to complement daily toothbrushing routine. From August 2023, Prodentis KIDS will be available for purchase via BioGaia's Swedish webshop, www.biogaia.se as well as the online pharmacies MEDS and Apotea. The recommended retail price is SEK 199.
공시 • Aug 03BioGaia Appoints Theresa Agnew as New CEO, Effective September 25, 2023BioGaia's board of directors has appointed Theresa P. Agnew as the new chief executive officer. Theresa Agnew is a global business leader with consumer healthcare, OTC, and medical device experience from leading companies such as GlaxoSmithKline (GSK), Essilor and Johnson & Johnson. She has extensive experience after more than 20 years in leadership roles, managing teams of more than 500 employees. She brings solid international experience having lived and worked in Europe, the US and Australia and the Far East. She has a deep understanding of, and success, in the international healthcare market(s). Theresa holds a B.S. in Biology from Boston College. At GSK she led their OTC global business across multiple segments of Pain Relief, Respiratory Health and Skin Health in OTC pharmaceuticals, naturals, supplements and medical devices in the largest OTC company worldwide. Currently, Theresa Agnew is working at a diabetes start-up, preparing for commercial launch and structuring the company to scale. Theresa Agnew will join the company subject to the successful completion of the pending work permit application process, with an expected starting date as of September 25, or such later date as may be necessary to comply with these requirements.
공시 • Jul 06BioGaia's probiotic Protectis increases SARS-CoV-2 antibody response in adultsA randomised, triple-blinded, placebo-controlled study with BioGaia's probiotic Protectis was shown to increase SARS-CoV-2 antibody titres in healthy volunteers when 28 days or more had elapsed from vaccination. It suggests that probiotic supplementation may enhance the long-term protection against breakthrough infections. The study included 159 healthy adults without prior SARS-CoV-2 infection or COVID-19 vaccination. The participants consumed either BioGaia Protectis (Limosilactobacillus reuteri DSM 17938) + 10 microgram vitamin D3, or a placebo product that contained only vitamin D3 for 6 months. During the intervention period 12 subjects were infected, and 17 were fully vaccinated and sampled 28 days or more postvaccination. The purpose of the study was to investigate the effect of probiotic supplementation of BioGaia Protectis on SARS-CoV-2 specific antibody responses after natural infection or vaccination. Even though the primary outcome, based on infected subjects, failed to reach a statistically significant difference between the intervention groups, vaccinated individuals who consumed BioGaia Protectis showed significantly increased IgA antibody levels when 28 days or more had elapsed from vaccination. The study was conducted at the Nutrition-Gut-Brain Interactions Research Centre, Örebro University, Sweden. The results suggest that BioGaia Protectis may improve long-term protection against breakthrough infections after vaccination. The same type of antibodies that are increased by probiotics in this study have previously been shown to be protective against breakthrough infections.